Log in

NASDAQ:CRIS - Curis Stock Price, Forecast & News

-0.27 (-14.67 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
Now: $1.57
50-Day Range
MA: $1.83
52-Week Range
Now: $1.57
Volume2.28 million shs
Average Volume315,605 shs
Market Capitalization$52.13 million
P/E RatioN/A
Dividend YieldN/A
Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:CRIS



Sales & Book Value

Annual Sales$10.43 million
Book Value($0.14) per share


Net Income$-32,580,000.00
Net Margins-299.47%


Market Cap$52.13 million
Next Earnings Date3/24/2020 (Estimated)

Receive CRIS News and Ratings via Email

Sign-up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter.

Curis (NASDAQ:CRIS) Frequently Asked Questions

What is Curis' stock symbol?

Curis trades on the NASDAQ under the ticker symbol "CRIS."

When did Curis' stock split? How did Curis' stock split work?

Curis's stock reverse split before market open on Wednesday, May 30th 2018. The 1-5 reverse split was announced on Tuesday, May 22nd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 29th 2018. An investor that had 100 shares of Curis stock prior to the reverse split would have 20 shares after the split.

How were Curis' earnings last quarter?

Curis, Inc. (NASDAQ:CRIS) released its quarterly earnings data on Tuesday, November, 5th. The biotechnology company reported ($0.19) EPS for the quarter. The biotechnology company had revenue of $2.86 million for the quarter. View Curis' Earnings History.

When is Curis' next earnings date?

Curis is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for Curis.

Has Curis been receiving favorable news coverage?

Media headlines about CRIS stock have been trending extremely negative this week, InfoTrie reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Curis earned a coverage optimism score of -4.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Curis.

Are investors shorting Curis?

Curis saw a decline in short interest in the month of November. As of November 15th, there was short interest totalling 189,000 shares, a decline of 49.0% from the October 31st total of 370,800 shares. Based on an average daily trading volume, of 150,300 shares, the days-to-cover ratio is presently 1.3 days. Approximately 0.7% of the company's shares are sold short. View Curis' Current Options Chain.

Who are some of Curis' key competitors?

What other stocks do shareholders of Curis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Celldex Therapeutics (CLDX), Micron Technology (MU), Novavax (NVAX), Zynga (ZNGA), Synergy Pharmaceuticals (SGYP), Jones Energy (JONE), CTI BioPharma (CTIC), Agenus (AGEN) and Idera Pharmaceuticals (IDRA).

Who are Curis' key executives?

Curis' management team includes the folowing people:
  • Mr. James E. Dentzer, Pres, CEO & Director (Age 52)
  • Dr. Robert E. Martell, Head of R&D (Age 56)
  • Mr. Mark W. Noel, VP of Technology Management & Intellectual Property (Age 60)
  • Mr. Bill Steinkrauss, Corp. Controller & Sr. Director of Fin.
  • Mr. Daniel R. Passeri M.Sc., MSc., J.D., Consultant (Age 58)

Who are Curis' major shareholders?

Curis' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Orbimed Advisors LLC (3.74%), Arnhold LLC (1.25%), BB&T Securities LLC (0.13%) and Sunbelt Securities Inc. (0.04%). Company insiders that own Curis stock include James E Dentzer, Kenneth I Kaitin and Robert Martell. View Institutional Ownership Trends for Curis.

Which major investors are selling Curis stock?

CRIS stock was sold by a variety of institutional investors in the last quarter, including Arnhold LLC. Company insiders that have sold Curis company stock in the last year include James E Dentzer, Kenneth I Kaitin and Robert Martell. View Insider Buying and Selling for Curis.

Which major investors are buying Curis stock?

CRIS stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, BB&T Securities LLC and Sunbelt Securities Inc.. View Insider Buying and Selling for Curis.

How do I buy shares of Curis?

Shares of CRIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Curis' stock price today?

One share of CRIS stock can currently be purchased for approximately $1.57.

How big of a company is Curis?

Curis has a market capitalization of $52.13 million and generates $10.43 million in revenue each year. Curis employs 55 workers across the globe.View Additional Information About Curis.

What is Curis' official website?

The official website for Curis is http://www.curis.com/.

How can I contact Curis?

Curis' mailing address is 4 MAGUIRE ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 617-503-6500 or via email at [email protected]

MarketBeat Community Rating for Curis (NASDAQ CRIS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  569 (Vote Outperform)
Underperform Votes:  502 (Vote Underperform)
Total Votes:  1,071
MarketBeat's community ratings are surveys of what our community members think about Curis and other stocks. Vote "Outperform" if you believe CRIS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRIS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel